Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review

Sara Rahavi-Ezabadi; Sheng Zhou; Stella E Lee; Elisabeth Ference; Anthony Magit; Shelby Leuin; Kawthar Mohamed; Nima Rezaei; Vijay A Patel

doi:10.1002/ohn.717

Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review

Otolaryngol Head Neck Surg. 2024 Mar 15. doi: 10.1002/ohn.717. Online ahead of print.

Authors

Sara Rahavi-Ezabadi¹, Sheng Zhou², Stella E Lee³, Elisabeth Ference⁴, Anthony Magit^{5

6}, Shelby Leuin^{5

6}, Kawthar Mohamed^{7

8}, Nima Rezaei^{9

10}, Vijay A Patel^{5

6}

Affiliations

¹ Department of Otorhinolaryngology-Head and Neck Surgery, Otorhinolaryngology Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
² USC Caruso Department of Otolaryngology-Head and Neck Surgery, Los Angeles, California, USA.
³ Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁴ Department of Otolaryngology, Facey Medical Group, Los Angeles, California, USA.
⁵ Department of Otolaryngology-Head and Neck Surgery, University of California San Diego, La Jolla, California, USA.
⁶ Division of Pediatric Otolaryngology, Rady Children's Hospital-San Diego, San Diego, California, USA.
⁷ School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
⁸ Network of Empirical, Gustatory, and Olfactory Aesthetics (NEGOA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
⁹ Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
¹⁰ Network of Immunity in Infection Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.

PMID: 38488239
DOI: 10.1002/ohn.717

Abstract

Objective: Provide clinicians with current evidence for biologic therapy in children with chronic rhinosinusitis with nasal polyposis (CRSwNP).

Data sources: PubMed, MEDLINE, Cochrane, and clinical trial registries.

Review methods: Key search terms related to biologic therapy in pediatric CRSwNP were identified via a structured query of current medical literature and clinical trial databases.

Conclusions: There is a dearth of active clinical trials and research studies for biologics targeting pediatric CRSwNP. There is an ongoing compassionate-use clinical trial involving Dupilumab for children with nasal polyps as well as only 1 published work specifically focused on Dupilumab for pediatric CRSwNP in the setting of aspirin-exacerbated respiratory disease.

Implications for practice: For children with atopic dermatitis, asthma, and chronic idiopathic urticaria, biologic therapies such as Omalizumab, Dupilumab, and Mepolizumab have gained Food and Drug Administration approval. The role of biologic therapy in pediatric CRSwNP demonstrates significant promise in the comprehensive management of the unified airway. Additional Phase III trials are necessary to broaden clinical indications for children with comorbid conditions and complex sinonasal disease.

Keywords: biologics children; chronic rhinosinusitis; mAb; nasal polyps; pediatric; rhinosinusitis.

Publication types

Review